A 59-year-old police officer with prostate cancer was treated with the Elekta Unity MR-Linac, a breakthrough innovation that simultaneously generates magnetic resonance images and delivers radiation directly to the tumors.
Andrew “AC” Jones has long been a leader with a passion to serve others.
As a Pittsburgh Bureau of Police officer for the last 27 years, AC had dedicated his career to building relationships and trust in the community. He spent much of his career as a patrol officer in the North Side, getting to know residents to help make neighborhoods safer.
So when AC was diagnosed with prostate cancer last year, true to form, he volunteered to be the first patient treated with a new radiotherapy technology at the AHN Cancer Institute.
“I said, ‘Sign me up.’ Whatever it takes, and maybe it will help other people down the line.”
Last June, the 59-year-old was treated with the Elekta Unity MR-Linac. It’s a breakthrough innovation that simultaneously generates magnetic resonance images (MRI) and delivers radiation directly to the tumors. The AHN Cancer Institute is one of the few facilities in the country and the first in Pennsylvania to have the MR-Linac.
“We can see the tumor in real time as a patient moves and breathes, and we can adapt the radiation dose right there during the treatment,” said Russell Fuhrer, MD, system director for AHN Radiation Oncology. “Then each time a patient comes for treatment, we begin with all new MRIs for the most accurate radiation delivery”.
Unity MR-Linac is a hybrid technology that integrates an MRI scanner with a linear accelerator. It gives oncologists and physicists a sharp and well-defined view of the shape, size, and position of a tumor, so they can target the cancer with pinpoint precision.
“This technology lets us treat the cancer so precisely for each patient,” Dr. Fuhrer said. “We’ve never had such accuracy before in radiation oncology, so this is very exciting that patients could possibly experience fewer treatments, minimal side effects, and better outcomes.”
“We’ve never had such accuracy before in radiation oncology.” — Dr. Russell Fuhrer
AC had just five treatments over 10 days. He was tired after the first treatment and didn’t make it to work at the City of Pittsburgh Warrant Office that day. But he bounced back and was ready to go after the next four treatments.
“I do what I got to do and keep on living. The whole staff at Allegheny, they kept me upbeat and positive, and they were so good to me,” AC said. “Dr. Fuhrer and all of them have been a godsend.”
Dr. Fuhrer said it’s too early to say if AC is cancer-free, but added that the goal is to cure him without surgery.
“Men with prostate cancer typically have several treatment options,” Dr. Fuhrer explained. “Improving the precision and shortening the number of visits of radiotherapy with the Unity MR-Linac makes it a good option for more men.”
AC praised his three grown daughters, Meagan, Monica, and Paige, his siblings, friends, and colleagues for supporting him and keeping him optimistic through his cancer battle.
“The day I rang the bell down there, I got very emotional. It really is a blessing, and to have all of these people who support you, it’s something else.”
The AHN Cancer Institute is part of an international research consortium to address how the MR-Linac could be used to improve patient survival and quality of life. The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center are two other U.S. facilities involved.
Patients with prostate, liver, pancreatic, and metastatic tumors are candidates for the Unity treatment. AHN physicians will also study treating head and neck, lung, breast, and gastrointestinal cancers.
“It may also be an effective option for recurrent or previously treated tumors that we can’t treat with standard therapies,” said Tom Colonias, MD, AHN director of Thoracic Malignancies in Radiation Oncology. “We will study how best to use the MR-Linac for these challenging cases.”
“It may also be an effective option for recurrent or previously treated tumors that we can’t treat with standard therapies.” — Dr. Tom Colonias
Reach Dr.Fuhrer at 412-953-3337 or email@example.com, and Dr.Colonias at 412-580-5990 or firstname.lastname@example.org.